A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
About
Brief Summary
The primary objective of this study is to assess the long-term safety of vatiquinone in participants with Friedreich ataxia (FA) previously exposed to vatiquinone.
Primary Purpose
Study Type
Phase
Eligibility
Gender
Healthy Volunteers
Minimum Age
Maximum Age
Inclusion Criteria:
- Participants with FA who completed and directly rolled over from a previous vatiquinone clinical study.
- Males and females of childbearing potential must be willing to use an effective method of contraception (for example, implants, injectables, transdermal patches, combined oral contraceptives, barrier methods, and intrauterine devices) from the time consent is signed until 30 days after the last dose of study drug or Early Termination Visit.
Exclusion Criteria:
- Current participation in any other interventional study
- Pregnancy or breastfeeding
Join this Trial
Enrolling by Invitation
These studies are not open to everyone who meets the eligibility criteria, but
only to people in that particular population, who are specifically invited to participate.
Study Stats
Protocol No.
22-001496
Category
Brain/Neurological Diseases
Genetic and Rare Diseases
Principal Investigator
Contact
Location
- UCLA Westwood